The 10-year failure gap most short-term data misses

Roughly one in seven athletes who underwent OATS experienced treatment failure by the ten-year mark. Among those who had microfracture, the figure was more than one in three.

That disparity comes from Gudas et al. (American Journal of Sports Medicine, 2012), the only prospective randomised controlled trial comparing the two techniques exclusively in young athletes to reach a full decade of follow-up. Its headline finding — 14% failure with OATS (mosaicplasty) versus 38% with microfracture, a statistically significant difference (P<0.05) — is not a marginal quirk of trial design. It represents a clinically meaningful gap in how well each procedure holds up under years of athletic demand.

What makes the finding particularly important for patients weighing up mixed evidence online is the timing of that divergence. At short-term assessment, both groups looked broadly equivalent; the gap only became apparent between years five and ten, as microfracture outcomes progressively declined while mosaicplasty results remained stable. Short-term trials that report microfracture performing well may therefore be capturing a window before the deterioration takes hold — systematically underestimating the procedure's longer-term failure trajectory.

Muthu et al.'s 2024 network meta-analysis, drawing on a broader pool of studies rather than a single trial, independently reaches the same directional conclusion: mosaicplasty produces significantly better functional outcomes at the ten-year point than microfracture. The consistency of that finding across two methodologically distinct analyses strengthens the overall weight of evidence.

Why microfracture's repair tissue degrades under sport

Microfracture works by puncturing the subchondral bone to release marrow-derived stem cells into the defect, which then clot and differentiate into repair tissue. That repair tissue is fibrocartilage — a structurally different material from the native hyaline cartilage it replaces. Fibrocartilage lacks the ordered collagen architecture, load-distribution capacity, and wear resistance of true articular cartilage. It functions, in effect, as a provisional patch: adequate for lighter demands, but not built for the repetitive compressive and shearing forces that competitive sport generates at the knee.

OATS takes a different approach entirely. Rather than stimulating the body to grow a substitute tissue, it transplants cylindrical cores of native hyaline cartilage — harvested from a lower-load region of the same knee — directly into the defect. The implanted material is structurally equivalent to what it replaces: the same collagen type, the same mechanical architecture, the same capacity to withstand high-impact loading.

Under the pivoting, decelerating, and high-impact demands of athletic sport, fibrocartilage degrades progressively. This is not a random failure pattern; it follows logically from what the tissue is made of. Hyaline grafts, by contrast, have demonstrated stability at ten years in athlete-specific follow-up data. The biological difference between the two repair tissues is precisely why the performance gap does not appear immediately — both procedures typically reduce pain in the early post-operative period — but widens as cumulative athletic load takes its toll on the mechanically weaker material.

What function and activity scores look like at a decade

The Tegner activity scale measures how physically demanding a patient's sport or daily activity is — a score of 9–10 corresponds to competitive football or heavy manual labour; scores around 4–5 reflect recreational walking or cycling. At the ten-year point, OATS patients held significantly higher Tegner scores than the microfracture group, meaning more of them were sustaining demanding activity rather than stepping down to lighter exercise. The ICRS score — a structured assessment of cartilage tissue quality — showed the same directional result: OATS-treated knees scored significantly better on tissue architecture and repair fill.

Pareek et al.'s 2016 systematic review adds broader context: successful long-term outcomes were recorded in 78% of patients, with increased age at surgery and a history of prior knee procedures emerging as the strongest predictors of failure.

Ulstein et al. (2014) provide a genuine counterpoint that should not be dismissed. In a randomised trial of 25 patients followed to a median of 9.8 years, Lysholm scores, KOOS subscales, muscle strength, and radiographic osteoarthritis showed no statistically significant difference between the two techniques. That is a real finding — but with 25 patients drawn from a mixed-activity population, the study lacks the statistical power to detect differences of the magnitude Gudas observed in young competitive athletes specifically.

The most instructive number from Ulstein sits beneath the headline result: absolute Lysholm scores of approximately 69 (microfracture) and 63 (OATS) indicate that, for a meaningful proportion of patients, neither procedure fully restores pre-injury functional capacity. Both represent real improvements from a painful, damaged baseline — but the gap from healthy function persists, and communicating that honestly matters for pre-surgical decision-making.

The patient profile where the evidence applies — and where it does not

Population matters as much as technique. The headline failure-rate difference comes from Gudas et al.'s trial of young competitive athletes — and studies in general, mixed-activity populations consistently find no statistically significant difference between OATS and microfracture at equivalent follow-up lengths. Athletic demand appears to be the moderating variable: the outcome gap emerges specifically where joints face years of high-impact, pivoting load. A predominantly sedentary patient, or one engaged only in low-impact recreation, sits outside the evidence base that drives the OATS advantage.

Patient anatomy and history carry equal weight. OATS is contraindicated where BMI exceeds 40, where age is above 50, or where the joint already shows osteoarthritis beyond Kellgren-Lawrence grade 2 — any of which substantially alters the biological environment into which a graft would be placed. Prior knee surgery and older age at the time of the procedure are also established predictors of poorer long-term OAT outcomes. Lesion size is another hard boundary: OATS is suited to defects of roughly 1–2 cm²; the mosaic technique can extend coverage to approximately 4 cm², but larger or diffuse cartilage loss lies outside the procedure's scope.

Microfracture, meanwhile, still delivers clinically meaningful short-to-medium term benefit even in athletes. A 2025 systematic review in the Knee Surgery, Sports Traumatology, Arthroscopy journal found a 94% return-to-play rate, with 74% of athletes returning at their previous level — figures any patient weighing the options deserves to hear.

The selection question ultimately resolves around three things: who the patient is, what the imaging shows, and what physical demands they intend to return to.

Trade-offs both procedures carry

Both procedures carry costs the headline failure figures do not capture.

OATS requires harvesting osteochondral plugs from a less-loaded region of the same knee. Donor-site morbidity — localised pain, occasional stiffness, and in some cases cartilage disruption at the harvest site — is a documented trade-off that patients weighing the procedure should factor in. Pareek et al.'s 2016 review notes that prior surgery within the joint is a predictor of poorer OAT outcomes, a consideration that extends to any future intervention in the same knee.

The practical problem with microfracture failure is not simply that repair tissue degrades over time — it is that the preceding bone disruption can narrow the revision options available later. Patients who require a second procedure following failed microfracture may find the altered subchondral environment complicates graft integration, making outcomes of any subsequent surgery harder to predict.

Technical execution adds a further layer to the OATS calculation. Plug orientation, congruence with the surrounding cartilage surface, and press-fit stability all influence graft integration — surgical experience is a meaningful outcome variable, not a fixed background condition.

Beyond the operative factors, psychological barriers — fear of re-injury, pressure around team selection, and career uncertainty — are documented reasons why athletes do not return to sport regardless of how well a procedure goes. Taken together with the absolute Lysholm scores of approximately 63–69 that Ulstein's ten-year data showed across both techniques, the realistic horizon for most patients is meaningful improvement in pain and sustained high-level activity — not a guaranteed return to the precise performance baseline they held before injury.

What to consider when neither technique fits your profile

Some patients arrive at this comparison having already been told that OATS is not suitable — BMI, age, OA grade, or defect size rules it out — or that microfracture carries too much long-term risk for someone with athletic ambitions. For them, the decade-long trial data provides useful clinical context, but not a direct decision pathway.

Two alternatives are worth knowing. AMIC (autologous matrix-induced chondrogenesis) was developed partly in response to microfracture's fibrocartilage limitation: it augments the marrow-stimulation step with a collagen matrix that provides structural scaffolding for the repair tissue, bridging toward more durable regenerative repair in a single stage.

ChondroFiller injection — available in the UK as Liquid Cartilage™ through the London Cartilage Clinic on Harley Street — represents a different pathway category entirely. As an acellular injectable collagen scaffold placed under ultrasound guidance as an outpatient procedure, it supports matrix-induced chondrogenesis without requiring donor-site harvest. The treated defect range extends to 3 cm² and, in suitable cases, to 6 cm². The intent here is not to draw a direct outcome comparison with OATS or microfracture — it occupies a distinct procedural tier and addresses a different clinical decision point.

The right question is not "OATS or microfracture?" but which technique maps best to a particular defect size, joint condition, age, activity goal, and surgical history. A structured cartilage assessment is designed to answer exactly that — and one can be arranged via londoncartilage.com.